| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
11,270,000 |
| Market
Cap: |
290.65(M) |
| Last
Volume: |
197,427 |
Avg
Vol: |
196,888 |
| 52
Week Range: |
$13.82 - $26.5 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile XOMA is a biotech royalty aggregator. Co. has a portfolio of economic rights to milestone and royalty payments associated with partnered pre-commercial therapeutic candidates. Co.'s portfolio was built through licensing its proprietary products and platforms from its discovery and development business, combined with acquisitions of rights to milestones and royalties.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
5,250 |
117,800 |
| Total Buy Value |
$0 |
$0 |
$74,754 |
$2,088,813 |
| Total People Bought |
0 |
0 |
2 |
3 |
| Total Buy Transactions |
0 |
0 |
5 |
21 |
| Total Shares Sold |
0 |
0 |
0 |
27,000 |
| Total Sell Value |
$0 |
$0 |
$0 |
$809,425 |
| Total People Sold |
0 |
0 |
0 |
2 |
| Total Sell Transactions |
0 |
0 |
0 |
2 |
| End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Baker Julian |
Director |
– • • |
2014-12-12 |
4 |
S |
$4.71 |
$1,196,413 |
I/I |
(253,800) |
459,878 |
|
- |
|
| Limber Joseph M |
Director |
– • – |
2014-12-12 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,600 |
27,900 |
|
- |
|
| Baker Julian |
Director |
– • • |
2014-12-09 |
4 |
S |
$4.62 |
$1,811,062 |
I/I |
(392,353) |
465,335 |
|
- |
|
| Baker Julian |
Director |
– • • |
2014-12-04 |
4 |
S |
$4.55 |
$5,928,902 |
I/I |
(1,304,288) |
473,764 |
|
- |
|
| Baker Julian |
Director |
– • • |
2014-12-03 |
4 |
S |
$4.84 |
$2,748,837 |
I/I |
(567,918) |
501,850 |
|
- |
|
| Baker Julian |
Director |
– • • |
2014-12-02 |
4 |
S |
$5.36 |
$2,679,550 |
I/I |
(500,000) |
513,815 |
|
- |
|
| Scannon Patrick J Md Phd |
Exec. VP & CSO |
• • – |
2014-12-01 |
4 |
AS |
$5.51 |
$27,569 |
D/D |
(5,000) |
86,346 |
|
- |
|
| Neal James R |
VP Business Development |
– – – |
2014-11-26 |
4 |
S |
$5.67 |
$9,514 |
D/D |
(1,678) |
137,760 |
|
- |
|
| Neal James R |
VP Business Development |
• – – |
2014-11-24 |
4 |
AS |
$5.03 |
$5,193 |
D/D |
(1,032) |
139,438 |
|
- |
|
| Rubin Paul D |
Sr. VP Clinical Dev. & CMO |
• – – |
2014-11-20 |
4 |
AS |
$4.55 |
$22,750 |
D/D |
(5,000) |
72,021 |
|
- |
|
| Rubin Paul D |
Sr. VP Clinical Dev. & CMO |
• – – |
2014-11-20 |
4 |
OE |
$3.04 |
$15,200 |
D/D |
5,000 |
77,021 |
|
- |
|
| Kurland Fred |
CFO & VP Finance |
• – – |
2014-11-13 |
4 |
S |
$3.89 |
$34,148 |
D/D |
(8,773) |
85,086 |
|
- |
|
| Kurland Fred |
CFO & VP Finance |
• – – |
2014-11-13 |
4 |
OE |
$0.00 |
$0 |
D/D |
22,596 |
93,859 |
|
- |
|
| Van Ness W Denman |
Director |
– • – |
2014-11-13 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,875 |
45,027 |
|
- |
|
| Bowes William K Jr |
Director |
– • – |
2014-11-13 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,498 |
36,866 |
|
- |
|
| Walbert Timothy P |
Director |
– • – |
2014-11-13 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,498 |
35,795 |
|
- |
|
| Wyszomierski Jack L |
Director |
– • – |
2014-11-13 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,498 |
35,795 |
|
- |
|
| Scannon Patrick J Md Phd |
Exec. VP & CSO |
• • – |
2014-11-13 |
4 |
S |
$3.89 |
$32,093 |
D/D |
(8,245) |
91,346 |
|
- |
|
| Scannon Patrick J Md Phd |
Exec. VP & CSO |
• • – |
2014-11-13 |
4 |
OE |
$0.00 |
$0 |
D/D |
22,652 |
99,591 |
|
- |
|
| Neal James R |
VP Business Development |
• – – |
2014-11-13 |
4 |
S |
$3.89 |
$17,076 |
D/D |
(4,387) |
140,470 |
|
- |
|
| Varian John |
CEO |
• • – |
2014-11-13 |
4 |
S |
$3.89 |
$10,237 |
D/D |
(2,630) |
367,184 |
|
- |
|
| Varian John |
CEO |
• • – |
2014-11-13 |
4 |
OE |
$0.00 |
$0 |
D/D |
100,664 |
369,814 |
|
- |
|
| Scannon Patrick J Md Phd |
Exec. VP & CSO |
• • – |
2014-11-03 |
4 |
AS |
$4.33 |
$21,660 |
D/D |
(5,000) |
76,939 |
|
- |
|
| Rubin Paul D |
Sr. VP Clinical Dev. & CMO |
• – – |
2014-10-28 |
4 |
AS |
$4.57 |
$22,829 |
D/D |
(5,000) |
72,021 |
|
- |
|
| Rubin Paul D |
Sr. VP Clinical Dev. & CMO |
• – – |
2014-10-28 |
4 |
OE |
$3.04 |
$15,200 |
D/D |
5,000 |
77,021 |
|
- |
|
354 Records found
|
|
Page 12 of 15 |
|
|
0.55 (2.18%) 
